WADA prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Anti-nRNP antibody == Anti-nuclear Ribonucleoprotein (Anti-nRNP) antibodies are a type of autoantibody, which are antibodies that wrongly target and attack a person's own cells, proteins or tissues. In particular, anti-nRNPs are directed against nuclear ribonucleoproteins (nRNPs), which are complexes composed of proteins and nucleic acids. These ribonucleoproteins play a critical role in various cellular processes, including RNA processing and gene expression. Anti-U1 RNP antibodies target proteins that are part of the U1 small nuclear ribonucleoprotein (U1-snRNP) complex. This complex is involved in RNA splicing, a process that removes non-coding regions from pre-messenger RNA before it is translated into proteins. Because RNA splicing is necessary for normal cell function, problems involving the U1-snRNP complex are associated with several autoimmune connective tissue diseases. Although researchers do not understand why anti-U1 RNP antibodies develop, studies suggest that both genetic and environmental factors contribute to the loss of immune tolerance that allows these antibodies to form.
is the chemical potential in the standard state, R is the gas constant T is the absolute temperature, and Aj is the activity. For a closed system, no particles may enter or leave, although they may combine in various ways. The total number of atoms of each element will remain constant. This means that the minimization above must be subjected to the constraints:
== Complete proteins in non-human animals == Scientists had known since the early 20th century that rats could not survive on a diet whose only protein source was zein, which comes from maize (corn), but recovered if they were fed casein from cow's milk. This led William Cumming Rose to the discovery of the essential amino acid threonine. Through manipulation of rodent diets, Rose was able to show that ten amino acids are essential for rats: threonine, lysine, tryptophan, histidine, phenylalanine, leucine, isoleucine, methionine, valine, and arginine, the last of which is non-essential for humans. Rose's later work showed that eight amino acids are essential for adult human beings, with histidine also being essential for infants. Longer-term studies established histidine as also essential for adult humans.
At the meeting to close the deal, one of the bankers recorded, "Michael thought he was President of the Oxford Union again, and entered into a grand oration and bored everyone stiff". In 1971 Heseltine placed his shares in a trust controlled by his ministerial boss Peter Walker and by his solicitor Charles Corman. Haymarket's pretax profits were £453,000 in 1971 and £704,000 in 1972. Haymarket was due to be floated as a public company in the autumn of 1973, although this was cancelled because of the rise in the oil price, which reduced the profitability of the publishing industry. They thus avoided the stock market crash which followed. The company remains privately owned to this day. Heseltine acted as a consultant to Haymarket during his period out of government office between 1974 and 1979. His role was to bring in new publishing ideas. He believed he increased performance, although Robert Heller later recorded that he did very little, for he was too busy as a member of the Shadow Cabinet. He worked from an office at Haymarket, near Regent Street, rather than in the House of Commons. Under the management of Masters and Tindall, Haymarket continued to grow. By 1976 it was making annual profits of round £1.75m. In 1976–1977 Heseltine, Masters, Tindall and the Finance Director David Fraser bought out the consortium's 40% share, using money borrowed from them, giving Heseltine and his family over 50% control of Haymarket. Heseltine had taken out large personal loans both to increase his stake in the company and to buy his country mansion Thenford House.
==== MeSH D12.125.070 – amino acids, branched-chain ==== MeSH D12.125.070.075 – aminoisobutyric acids MeSH D12.125.070.577 – isoleucine MeSH D12.125.070.637 – leucine MeSH D12.125.070.950 – valine MeSH D12.125.070.950.100 – 2-amino-5-phosphonovalerate
Sources: en.wikipedia.org
=== Sample preparation === Conducting and semi-conducting samples may be directly analyzed after being formed into electrodes. Non-conductive samples are first powdered, mixed with a conducting powder (usually high purity graphite or silver), homogenized, and then formed into electrodes. Even liquids can be analyzed if they are frozen or after impregnating a conducting powder. Sample homogeneity is important for reproducibility.
By 25 September, an army of around 40,000 Iraqi, Syrian, and Houthi militants were concentrated around the Golan Heights, which the Institute for the Study of War argued was to defend against an Israeli invasion of Lebanon. The number of displaced Lebanese people reached an estimated 500,000. On 26 September, an Israeli strike on a three-story building in Younine killed at least 19 Syrians and a Lebanese person, mostly women or children, and injured eight others. On 27 September, Israel struck Hezbollah's central headquarters in Beirut, targeting Hezbollah leader Hassan Nasrallah. Al-Manar reported that four buildings collapsed in the attack. At least five other people died, including Ali Karaki, Hezbollah's commander of the southern front since 1982, and at least 100 were injured. On 28 September, the Lebanese National News Agency reported that IDF strikes struck civil defense centres and a medical clinic in Taybeh and Deir Siriane killing 11 medical staff and injuring 10 others. On 29 September, an Israeli air strike on a home in Dahr-al-Ain killed at least 11 people. The Lebanese National News Agency reported that at least 17 members of a family were killed and several others were trapped under rubble in an Israeli air strike in Zboud. An Israeli strike in Ain El Delb killed 45 people and injured at least 75 others. An Israeli strike in Bekaa killed 12 people and injured 20 others. On 30 September, Israel informed the United States that it intended to carry out a ground maneuver in Lebanon aimed at clearing Hezbollah's infrastructure along the border.
==== Synroc ==== The Australian Synroc (synthetic rock) is a more sophisticated way to immobilize such waste, and this process may eventually come into commercial use for civil wastes (it is currently being developed for U.S. military wastes). Synroc was invented by Ted Ringwood, a geochemist at the Australian National University. The Synroc contains pyrochlore and cryptomelane type minerals. The original form of Synroc (Synroc C) was designed for the liquid high-level waste (PUREX raffinate) from a light-water reactor. The main minerals in this Synroc are hollandite (BaAl2Ti6O16), zirconolite (CaZrTi2O7) and perovskite (CaTiO3). The zirconolite and perovskite are hosts for the actinides. The strontium and barium will be fixed in the perovskite. The caesium will be fixed in the hollandite. A Synroc waste treatment facility began construction in 2018 at ANSTO.
=== NPH insulin === NPH insulin, also known as isophane insulin, is an intermediate-acting insulin used to manage blood sugar levels in individuals with diabetes. The name NPH is an abbreviation for "neutral protamine Hagedorn", referring to neutral pH (pH = 7), protamine a protein attached to the insulin molecule, and Hans Christian Hagedorn, the insulin researcher who developed this formulation. It was designed to enhance insulin delivery and is one of the early examples of engineered drug delivery. It is typically administered through subcutaneous injection once or twice daily. Its effects usually begin within an hour and last for 24 hours. There are versions available that are premixed with short-acting insulins, such as regular insulin. The most common side effect is low blood sugar (hypoglycemia). Other potential side effects may include pain or skin changes at the injection sites, low blood potassium, and allergic reactions. It is generally considered safe for use during pregnancy for the fetus. NPH insulin is produced by mixing regular insulin and protamine in precise proportions with zinc and phenol to maintain a neutral pH and form crystals. There are versions based on human and pig insulin. Protamine insulin was first created in 1936, and NPH insulin was introduced in 1946. It is included in the World Health Organization's List of Essential Medicines In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.